Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD

Current Medical Research and Opinion

Volumn 28, Issue 12, 2012, Pages 1959-1967

  Thornton Snider, Julia ^a   Luna, Yesenia ^a   Wong, Ken S ^b   Zhang, Jie ^b   Chen, Susan S ^a   Gless, Patrick J ^a   Goldman, Dana P ^a,c  

^a PRECISION HEALTH ECONOMICS   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Chronic obstructive pulmonary disease; Inhaled corticosteroids; Medicare; Nested case control study; Pneumonia

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE; MOMETASONE FUROATE; TRIAMCINOLONE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PNEUMONIA; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGE FACTORS; AGED; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MEDICARE; MODELS, BIOLOGICAL; OUTPATIENTS; PNEUMOCOCCAL VACCINES; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; UNITED STATES;

EID: 84870469745     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.743459     Document Type: Article

References (25)

1. Chronic obstructive pulmonary disease (COPD). World Health Organization (WHO), November 2011. Available at: http://www.who.int/mediacentre/factsheets/ fs315/en/index.html [Last accessed 6 February 2012]
2. Kochanek K, Xu J, Murphy S, et al. Deaths: Preliminary Data for 2009. Hyattsville, MD: National Center for Health Statistics, 2011
3. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir 2004;23:932-46
4. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. Available at: http://www.goldcopd.org/Guidelineitem.asp? l1¼2&l2¼1&intId¼989 [Last accessed 17 March 2011]
5. Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010;5:189-95
6. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propi-onate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
7. Spencer S, Evans DJ, Karner C, Cates CJ. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;(10):CD007033
8. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6
9. Sharma G, Hanania NA, Shim YM. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6:573-80
10. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010;104:246-52
11. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374:712-19
12. Hennessy S, Bilker WB, Berlin JA, Strom BL. Factors influencing the optimal control-to-case ratio in matched case-control studies. Am J Epidemiol 1999;149:195-7
13. Taylor JM. Choosing the number of controls in a matched case-control study, some sample size, power and efficiency considerations. Stat Med 1986;5:29-36
14. Inhaled Steroids Approximate Dose Conversions for Adults. GRIPA, 2005. Available at: http://gripa.org/Documents/Pharmacy-tidbits/Steroid-Inhaler- Conversion-Chart-12-05-Pharmacy-Tidbit.pdf [Last accessed 22 December 2005]
15. Taylor JD. COPD and the response of the lung to tobacco smoke exposure. Pulm Pharmacol Ther 2010;23:376-83
16. Fleiss J, Levin B, Paik M. Statistical Methods for Rates and Proportions, 3rd edn. Hoboken, NJ: Wiley, 2003
17. PN3a-Blood cultures performed within 24 hours prior to or 24 hours after hospital arrival for patients who were transferred or admitted to the ICU within 24 hours of hospital arrival. Quality Position Statements. Center for Medicaid and Medicare Services (CMS), 2008. Available at: http://www.qualityforum. org/QPS/MeasureDetails.aspx?standardID¼343&print¼0 [Last accessed 7 February 2012]
18. Freedman DA, Berk RA. Weighting regressions by propensity scores. Eval Rev 2008;32:392-409
19. Akazawa M, Biddle AK, Stearns SC. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching. Clin Ther 2008;30 Spec No:1003-16
20. Hanania NA. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm Pharmacol Ther 2008;21:540-50
21. Health Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality (AHRQ), 2012. Available at: http://hcupnet.ahrq.gov/ HCUPnet.jsp [Last accessed 14 March 2012]
22. Singanayagam A, Chalmers JD, Hill AT. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. QJM 2010;103:379-85
23. Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010;36:751-7
24. Singanayagam A, Chalmers JD, Akram AR, Hill AT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011;38:36-41
25. Drummond M, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA, 2008;300:2407-16